loperamide

Trade name: imodium

Small moleculeapproved

Approved

Dec 28, 1976

Loperamide is a commonly used over-the-counter (OTC) and prescription medicine that is approved to help control symptoms of diarrhea, including Travelers’ Diarrhea. The maximum approved daily dose for adults is 8 mg per day for OTC use and 16 mg per day for prescription use. It is sold under the OTC brand name Imodium A-D, as store brands, and as generics. In vitro and animal studies show that IMODIUM® (loperamide hydrochloride) acts by slowing intestinal motility and by affecting water and electrolyte movement through the bowel. Loperamide binds to the opiate receptor in the gut wall. Consequently, it inhibits the release of acetylcholine and prostaglandins, thereby reducing propulsive peristalsis, and increasing intestinal transit time. Loperamide increases the tone of the anal sphincter, thereby reducing incontinence and urgency. Loperamide is also indicated for reducing the volume of discharge from ileostomies. In man, Loperamide prolongs the transit time of the intestinal contents. It reduces the daily fecal volume, increases the viscosity and bulk density, and diminishes the loss of fluid and electrolytes. Tolerance to the antidiarrheal effect has not been observed. Loperamide is an opioid receptor agonist and acts on the mu opioid receptors in the myenteric plexus large intestines; it does not affect the central nervous system like other opioids. It works specifically by decreasing the activity of the myenteric plexus which decreases the motility of the circular and longitudinal smooth muscles of the intestinal wall. This increases the amount of time substances stay in the intestine, allowing for more water to be absorbed out of the fecal matter. Loperamide also decreases colonic mass movements and suppresses the gastrocolic reflex. — NCATS

Clinical trial activity

76 trials · 110 clinical orgs · 31 marketing orgs

Phase 1
14
Phase 2
23
Phase 3
15
Phase 4
9

Earliest trial started Nov 1, 1996 (NCT00003057)

Timeline

1970s

  1. Dec 28, 1976

    Johnson and Johnson — Earliest FDA Approval

  2. Dec 28, 1976

    Johnson and Johnson — NDA Secondary Org

  3. Dec 28, 1976

    Johnson and Johnson — NDA Organization

1990s

  1. Aug 30, 1991

    Teva — Marketing Organization

  2. Sep 18, 1991

    Mylan — Marketing Organization

  3. Apr 30, 1992

    Allied Pharmaceutical Services — Marketing Organization

  4. Aug 28, 1992

    Fosun — Marketing Organization

  5. Aug 28, 1992

    Chartwell Pharmaceuticals — Marketing Organization

  6. Sep 15, 1992

    Alpharma — Marketing Organization

  7. Dec 10, 1992

    Ohm Laboratories, Inc. — Marketing Organization

  8. Jul 30, 1993

    Contract Pharmacal — Marketing Organization

  9. Nov 30, 1993

    Able Laboratories — Marketing Organization

  10. Nov 17, 1995

    Hi Tech Pharmaceuticals — Marketing Organization

  11. Nov 17, 1995

    Saptalis Pharmaceuticals — Marketing Organization

  12. Nov 17, 1995

    Akorn, Inc. — Marketing Organization

  13. Nov 17, 1995

    Sciegen Pharmaceticals — Marketing Organization

  14. Jan 1, 1996

    Earliest Phase 3 Sponsor(trial)

  15. Aug 28, 1997

    Wockhardt — Marketing Organization

  16. Dec 29, 1997

    Duramed Research — Marketing Organization

2000s

  1. Jan 6, 2000

    Perrigo — Marketing Organization

  2. Jan 1, 2002

    Earliest Phase 1 Sponsor(trial)

  3. Jun 10, 2003

    LNK International — Marketing Organization

  4. Aug 4, 2005

    Bionpharma Inc — NDA Secondary Org

  5. Aug 4, 2005

    Bionpharma Inc — Marketing Organization

  6. Sep 6, 2006

    Sun Pharmaceuticals — Marketing Organization

  7. Jan 1, 2008

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Dec 15, 2015

    Aurobindo Pharma — Marketing Organization

2020s

  1. May 27, 2021

    Guardian Drug — Marketing Organization

  2. Jun 17, 2021

    Hetero Labs Ltd — Marketing Organization

  3. Aug 11, 2021

    Strides Pharma Science — Marketing Organization

  4. Oct 6, 2021

    Edenbridge Pharms — Marketing Organization

  5. Aug 29, 2022

    Granules India — Marketing Organization

  6. Jan 26, 2023

    Rubicon Research — Marketing Organization

  7. Mar 23, 2023

    Zydus Discovery DMCC — Marketing Organization

  8. Jul 5, 2023

    Jubilant Innovation Ltd. — Marketing Organization

Indications

Approved for

Mechanism of action

Combination products

Approval history

  • approvedDec 28, 1976

Chemistry & pharmacology

Loading structure…

SMILES

CN(C)C(=O)C(CCN1CCC(O)(c2ccc(Cl)cc2)CC1)(c1ccccc1)c1ccccc1
Mol. weight
477.05 g/mol
Lipinski Ro5
1 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Oral
Availability
Over the Counter

Oral

Yes

Parenteral

No

Topical

No

Black box warning

Sources

Also known as

  • arestal
  • arret
  • desmethyl-loperamide
  • desmethyl-loperamide
  • diah-limit
  • diaquitte
  • diareze
  • diarrhoea relief
  • diasorb
  • diasorb
  • diasorb
  • diocalm
  • diocaps
  • dioraleze
  • entrocalm
  • gppe pack
  • imodium
  • imodium
  • imodium
  • imodium
  • imodium a-d
  • imodium a-d
  • imodium a-d ez chews
  • imodium a-d ez chews
  • imodium advanced
  • imodium advanced
  • imodium classic
  • imodium ibs relief
  • imodium instant melts
  • imodium instants
  • imodium liquicaps
  • lodiar
  • loperagen
  • loperamid
  • loperamid
  • loperamida
  • loperamida
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • loperamide
  • lopéramide
  • lopéramide
  • loperamide hcl
  • loperamide hcl
  • loperamide hcl
  • loperamide hydrochloride
  • loperamide hydrochloride
  • loperamide hydrochloride
  • loperamide hydrochloride
  • loperamide hydrochloride
  • loperamide oxide
  • loperamide oxide
  • loperamide oxide monohydrate
  • loperamide oxide monohydrate
  • loperamide oxide monohydrate
  • loperamide oxide monohydrate
  • loperamidum
  • loperamidum
  • norimode
  • normaloe
  • r-18553
  • r-18553

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07195656N/ASep 30, 2025FemPulse Corporation
NCT06892093N/AAug 7, 2025Jiangnan University, Sun Yat-Sen University
NCT06971172N/AJun 1, 2025Cairo University
NCT06946979N/AApr 30, 2025Zhejiang Chinese Medical University
NCT06883864N/AApr 1, 2025Abbott, Capital Medical University
NCT06693934N/ANov 30, 2024Asia Diabetes Foundation, Chinese University of Hong Kong
NCT06299514N/AApr 25, 2024University of Western Ontario
NCT07016451Early Phase 1 (Phase 1)Apr 2, 2024Mahidol University
NCT06377826N/AApr 1, 2024Riphah International University
NCT06261801N/AFeb 7, 2024Hangzhou Third Hospital, Zhejiang University
NCT06101368N/AJan 1, 2024Health Education Research Foundation (HERF), University of Hail
NCT05520723Phase 2Jan 11, 2023Gilead Sciences, MedSIR, University of Barcelona
NCT05677282Phase 4Oct 28, 2022Henry M. Jackson Foundation for the Advancement of Military Medicine, Uniformed Services University of the Health Sciences
NCT05252988Phase 2Aug 31, 2022Hospital General Universitario Gregorio Marañon, Pierre Fabre, Puma Biotechnology, Inc., Spanish Breast Cancer Research Group
NCT05480566N/AJun 1, 2022Hasselt University
NCT05252546Phase 1Mar 8, 2022Hengrui Therapeutics, Inc.
NCT04576208Phase 2Nov 30, 2020Takeda
NCT04594226N/ANov 30, 2020Lishui Hospital of Traditional Chinese Medicine, Zhejiang University
NCT04446299Phase 3Jul 13, 2020Braintree Laboratories, Sebela Pharmaceuticals
NCT04446312Phase 3Jul 13, 2020Braintree Laboratories, Sebela Pharmaceuticals
Showing 20 of 76 trials
Page 1 / 4

Organizations

Research & Development (110)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Johnson and JohnsonFor profit4432005
Puma Biotechnology, Inc.For profit4212015
University of Texas at HoustonAcademic/Hospital4322002
Columbia UniversityAcademic/Hospital3132012
Duke UniversityAcademic/Hospital3032012
Eli LillyFor profit3322015
Zhejiang UniversityAcademic/Hospital3212020
Boehringer IngelheimFor profit2222002
Braintree LaboratoriesFor profit2212020
Cairo UniversityAcademic/Hospital2212018
Cedars-Sinai Medical CenterAcademic/Hospital2122012
Department of Veteran AffairsGovernment2222007
Hengrui Therapeutics, Inc.For profit2212020
Linkoping UniversityAcademic/Hospital2212002
McNeilFor profit2122008
National Cancer Institute (NCI)Government2021996
National Heart, Lung, and Blood Institute (NHLBI)Government2022012
New York UniversityAcademic/Hospital2222012
Sebela PharmaceuticalsFor profit2012020
Stanford UniversityAcademic/Hospital2022012
110 organizations
Page 1 / 6

Marketing (37)

OrganizationOrg typeRelationshipDate
Able LaboratoriesFor profitMKTGNov 30, 1993
Akorn, Inc.For profitMKTGNov 17, 1995
Allied Pharmaceutical ServicesFor profitMKTGApr 30, 1992
AlpharmaFor profitMKTGSep 15, 1992
Aurobindo PharmaFor profitMKTGDec 15, 2015
Aurobindo PharmaFor profitSYNDec 15, 2015
Bionpharma IncFor profitNDA2Aug 4, 2005
Bionpharma IncFor profitMKTGAug 4, 2005
Chartwell PharmaceuticalsFor profitMKTGAug 28, 1992
Contract PharmacalFor profitMKTGJul 30, 1993
Duramed ResearchFor profitMKTGDec 29, 1997
Edenbridge PharmsFor profitMKTGOct 6, 2021
FosunFor profitMKTGAug 28, 1992
Granules IndiaFor profitMKTGAug 29, 2022
Guardian DrugFor profitMKTGMay 27, 2021
Hetero Labs LtdFor profitMKTGJun 17, 2021
Hi Tech PharmaceuticalsFor profitMKTGNov 17, 1995
Johnson and JohnsonFor profitNDA2Dec 28, 1976
Johnson and JohnsonFor profitSYNJul 31, 1984
Johnson and JohnsonFor profitNDADec 28, 1976
Jubilant Innovation Ltd.For profitMKTGJul 5, 2023
LNK InternationalFor profitMKTGJun 10, 2003
MylanFor profitMKTGSep 18, 1991
Ohm Laboratories, Inc.For profitMKTGDec 10, 1992
PerrigoFor profitMKTGJan 6, 2000
PerrigoFor profitSYNJan 21, 1992
PerrigoFor profitSYNMay 20, 2011
Roxane LaboratoriesFor profitMKTG
Rubicon ResearchFor profitMKTGJan 26, 2023
Saptalis PharmaceuticalsFor profitMKTGNov 17, 1995
Sciegen PharmaceticalsFor profitMKTGNov 17, 1995
Strides Pharma ScienceFor profitMKTGAug 11, 2021
Sun PharmaceuticalsFor profitMKTGSep 6, 2006
TevaFor profitMKTGAug 30, 1991
Watson PharmaceuticalsFor profitMKTG
WockhardtFor profitMKTGAug 28, 1997
Zydus Discovery DMCCFor profitMKTGMar 23, 2023